Symbols / IDYA Stock $31.67 -0.50% IDEAYA Biosciences, Inc.
IDYA (Stock) Chart
About
No company description available for this symbol.
Stock Fundamentals
Scroll to Statements| Market Cap | 2.78B | Enterprise Value | — | Income | — | Sales | — | Book/sh | — | Cash/sh | — |
| Dividend Yield | — | Payout | — | Employees | — | IPO | — | P/E | — | Forward P/E | — |
| PEG | — | P/S | — | P/B | — | P/C | — | EV/EBITDA | — | EV/Sales | — |
| Quick Ratio | — | Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | — | EPS next Y | — |
| EPS Growth | — | Revenue Growth | — | Earnings | — | ROA | — | ROE | — | ROIC | — |
| Gross Margin | — | Oper. Margin | — | Profit Margin | — | Shs Outstand | — | Shs Float | — | Short Float | — |
| Short Ratio | — | Short Interest | — | 52W High | — | 52W Low | — | Beta | — | Avg Volume | — |
| Volume | — | Target Price | — | Recom | — | Prev Close | $31.83 | Price | $31.67 | Change | -0.50% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
Current target
—
Low
—
High
—
Mean
—
- IDYA (IDEAYA Biosciences Inc.) posts narrower than expected Q4 2025 loss, shares rise 4.31 percent. - Viral Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai hu, 23 Apr 2026 00
- IDEAYA gets late-breaking ASCO slot for full uveal melanoma data - Stock Titan ue, 21 Apr 2026 14
- Has The Market Overreacted To Recent Weakness In IDEAYA Biosciences (IDYA) Shares? - Yahoo Finance Mon, 02 Feb 2026 08
- Ideaya Biosciences: Key Pivotal Data Imminent - Seeking Alpha Wed, 08 Apr 2026 07
- Trading the Move, Not the Narrative: (IDYA) Edition - Stock Traders Daily ue, 21 Apr 2026 18
- Why Is Ideaya Biosciences (IDYA) Stock Surging Over 20% Overnight? - Stocktwits Mon, 13 Apr 2026 07
- IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial - PR Newswire Sun, 22 Mar 2026 07
- Why This Biotech Is Flying Into Breakout Territory - Investor's Business Daily Mon, 13 Apr 2026 07
- IDEAYA And AstraZeneca Collaboration Adds New Dimension To IDE849 And Valuation - simplywall.st Wed, 22 Apr 2026 02
- IDYA (IDEAYA Biosciences Inc.) reports narrower Q4 2025 loss than projections, but stock dips slightly in today's trading. - Pro Level Trade Signals - Xã Thanh Hà Wed, 22 Apr 2026 23
- Three experimental cancer programs to watch at April's big AACR meeting - Stock Titan Wed, 18 Mar 2026 07
- Is IDEAYA Biosciences (IDYA) stock risky for investors (Builds on Momentum) 2026-04-18 - AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai Sat, 18 Apr 2026 22
- IDEAYA drug combo held uveal melanoma for 6.9 months vs 3.1 - Stock Titan Mon, 13 Apr 2026 07
- IDEAYA to reveal April 13 trial data in metastatic uveal melanoma - Stock Titan Fri, 10 Apr 2026 07
- New cancer trial targets MTAP gene loss as IDEAYA shifts drug pipeline - Stock Titan Mon, 09 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
218.71
+3024.43%
|
7.00
-70.07%
|
23.39
-54.08%
|
50.93
|
| Operating Revenue |
|
218.71
+3024.43%
|
7.00
-70.07%
|
23.39
-54.08%
|
50.93
|
| Operating Expense |
|
378.02
+13.19%
|
333.98
+111.63%
|
157.81
+39.13%
|
113.43
|
| Research And Development |
|
314.70
+6.80%
|
294.67
+127.53%
|
129.51
+44.64%
|
89.54
|
| Selling General And Administration |
|
63.32
+61.11%
|
39.30
+38.85%
|
28.31
+18.45%
|
23.90
|
| General And Administrative Expense |
|
63.32
+61.11%
|
39.30
+38.85%
|
28.31
+18.45%
|
23.90
|
| Other Gand A |
|
63.32
+61.11%
|
39.30
+38.85%
|
28.31
+18.45%
|
23.90
|
| Total Expenses |
|
378.02
+13.19%
|
333.98
+111.63%
|
157.81
+39.13%
|
113.43
|
| Operating Income |
|
-159.31
+51.28%
|
-326.98
-143.23%
|
-134.43
-115.08%
|
-62.50
|
| Total Operating Income As Reported |
|
-159.31
+51.28%
|
-326.98
-143.23%
|
-134.43
-115.08%
|
-62.50
|
| EBITDA |
|
-154.72
+52.12%
|
-323.14
-147.77%
|
-130.42
-121.10%
|
-58.99
|
| Normalized EBITDA |
|
-154.72
+52.12%
|
-323.14
-147.77%
|
-130.42
-121.10%
|
-58.99
|
| Reconciled Depreciation |
|
4.59
+19.80%
|
3.83
-4.34%
|
4.01
+14.03%
|
3.52
|
| EBIT |
|
-159.31
+51.28%
|
-326.98
-143.23%
|
-134.43
-115.08%
|
-62.50
|
| Net Income |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Pretax Income |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Net Non Operating Interest Income Expense |
|
45.62
-13.11%
|
52.50
+144.54%
|
21.47
+458.05%
|
3.85
|
| Net Interest Income |
|
45.62
-13.11%
|
52.50
+144.54%
|
21.47
+458.05%
|
3.85
|
| Interest Income Non Operating |
|
45.62
-13.11%
|
52.50
+144.54%
|
21.47
+458.05%
|
3.85
|
| Interest Income |
|
45.62
-13.11%
|
52.50
+144.54%
|
21.47
+458.05%
|
3.85
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Net Income From Continuing Operation Net Minority Interest |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Net Income From Continuing And Discontinued Operation |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Net Income Continuous Operations |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Normalized Income |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Net Income Common Stockholders |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
2.16
|
| Diluted EPS |
|
—
|
-3.36
-71.43%
|
-1.96
-38.03%
|
-1.42
|
| Basic EPS |
|
—
|
-3.36
-71.43%
|
-1.96
-38.03%
|
-1.42
|
| Basic Average Shares |
|
—
|
81.68
+42.00%
|
57.52
+38.79%
|
41.44
|
| Diluted Average Shares |
|
—
|
81.68
+42.00%
|
57.52
+38.79%
|
41.44
|
| Diluted NI Availto Com Stockholders |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
649.32
|
| Current Assets |
|
532.63
|
| Cash Cash Equivalents And Short Term Investments |
|
525.11
|
| Cash And Cash Equivalents |
|
157.02
|
| Other Short Term Investments |
|
368.10
|
| Receivables |
|
0.02
|
| Accounts Receivable |
|
0.02
|
| Other Receivables |
|
—
|
| Prepaid Assets |
|
—
|
| Other Current Assets |
|
7.50
|
| Total Non Current Assets |
|
116.68
|
| Net PPE |
|
8.41
|
| Gross PPE |
|
18.02
|
| Accumulated Depreciation |
|
-9.61
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
1.00
|
| Other Properties |
|
13.70
|
| Leases |
|
3.32
|
| Investments And Advances |
|
107.49
|
| Other Non Current Assets |
|
0.78
|
| Total Liabilities Net Minority Interest |
|
28.23
|
| Current Liabilities |
|
27.10
|
| Payables And Accrued Expenses |
|
25.35
|
| Payables |
|
6.60
|
| Accounts Payable |
|
6.60
|
| Current Accrued Expenses |
|
18.76
|
| Current Debt And Capital Lease Obligation |
|
1.75
|
| Current Capital Lease Obligation |
|
1.75
|
| Current Deferred Liabilities |
|
0.00
|
| Current Deferred Revenue |
|
0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
1.12
|
| Long Term Debt And Capital Lease Obligation |
|
1.12
|
| Long Term Capital Lease Obligation |
|
1.12
|
| Non Current Deferred Liabilities |
|
0.00
|
| Non Current Deferred Revenue |
|
0.00
|
| Stockholders Equity |
|
621.09
|
| Common Stock Equity |
|
621.09
|
| Capital Stock |
|
0.01
|
| Common Stock |
|
0.01
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
65.04
|
| Ordinary Shares Number |
|
65.04
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
968.88
|
| Retained Earnings |
|
-348.36
|
| Gains Losses Not Affecting Retained Earnings |
|
0.56
|
| Other Equity Adjustments |
|
0.56
|
| Total Equity Gross Minority Interest |
|
621.09
|
| Total Capitalization |
|
621.09
|
| Working Capital |
|
505.53
|
| Invested Capital |
|
621.09
|
| Total Debt |
|
2.87
|
| Capital Lease Obligations |
|
2.87
|
| Net Tangible Assets |
|
621.09
|
| Tangible Book Value |
|
621.09
|
| Available For Sale Securities |
|
107.49
|
| Investmentin Financial Assets |
|
107.49
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-71.10
+71.28%
|
-247.58
-114.87%
|
-115.22
-32.18%
|
-87.17
|
| Cash Flow From Continuing Operating Activities |
|
-71.10
+71.28%
|
-247.58
-114.87%
|
-115.22
-32.18%
|
-87.17
|
| Net Income From Continuing Operations |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Depreciation Amortization Depletion |
|
4.59
+19.80%
|
3.83
-4.34%
|
4.01
+14.03%
|
3.52
|
| Depreciation |
|
4.59
+19.80%
|
3.83
-4.34%
|
4.01
+14.03%
|
3.52
|
| Depreciation And Amortization |
|
4.59
+19.80%
|
3.83
-4.34%
|
4.01
+14.03%
|
3.52
|
| Stock Based Compensation |
|
46.12
+32.72%
|
34.75
+87.93%
|
18.49
+58.99%
|
11.63
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Change In Working Capital |
|
1.87
-83.82%
|
11.55
+187.42%
|
-13.21
+69.26%
|
-42.97
|
| Change In Receivables |
|
0.00
|
0.00
-100.00%
|
0.19
-78.36%
|
0.89
|
| Changes In Account Receivables |
|
0.00
|
0.00
-100.00%
|
0.19
-78.36%
|
0.89
|
| Change In Prepaid Assets |
|
-7.84
-27.29%
|
-6.16
-201.17%
|
-2.04
+3.49%
|
-2.12
|
| Change In Payables And Accrued Expense |
|
13.12
-31.19%
|
19.07
+346.70%
|
4.27
-33.65%
|
6.44
|
| Change In Accrued Expense |
|
10.43
-3.40%
|
10.79
+560.18%
|
1.64
-64.24%
|
4.57
|
| Change In Payable |
|
2.70
-67.43%
|
8.28
+214.23%
|
2.63
+41.36%
|
1.86
|
| Change In Account Payable |
|
2.70
-67.43%
|
8.28
+214.23%
|
2.63
+41.36%
|
1.86
|
| Change In Other Working Capital |
|
-5.97
|
—
|
-13.75
+70.41%
|
-46.48
|
| Change In Other Current Assets |
|
—
|
—
|
—
|
1.41
|
| Change In Other Current Liabilities |
|
2.56
+286.78%
|
-1.37
+26.87%
|
-1.87
-10.18%
|
-1.70
|
| Investing Cash Flow |
|
69.98
+113.92%
|
-502.56
-217.16%
|
-158.46
-374.36%
|
-33.40
|
| Cash Flow From Continuing Investing Activities |
|
69.98
+113.92%
|
-502.56
-217.16%
|
-158.46
-374.36%
|
-33.40
|
| Net PPE Purchase And Sale |
|
-2.37
+38.61%
|
-3.86
-62.88%
|
-2.37
+31.22%
|
-3.44
|
| Purchase Of PPE |
|
-2.37
+38.61%
|
-3.86
-62.88%
|
-2.37
+31.22%
|
-3.44
|
| Capital Expenditure |
|
-2.37
+38.61%
|
-3.86
-62.88%
|
-2.37
+31.22%
|
-3.44
|
| Net Investment Purchase And Sale |
|
72.34
+114.51%
|
-498.70
-219.50%
|
-156.09
-420.97%
|
-29.96
|
| Purchase Of Investment |
|
-607.89
+48.97%
|
-1,191.31
-99.89%
|
-595.98
-132.98%
|
-255.81
|
| Sale Of Investment |
|
680.23
-1.79%
|
692.61
+57.45%
|
439.89
+94.77%
|
225.85
|
| Financing Cash Flow |
|
29.78
-95.60%
|
677.55
+86.80%
|
362.72
+273.30%
|
97.17
|
| Cash Flow From Continuing Financing Activities |
|
29.78
-95.60%
|
677.55
+86.80%
|
362.72
+273.30%
|
97.17
|
| Net Common Stock Issuance |
|
24.86
-96.20%
|
654.23
+111.20%
|
309.76
+226.20%
|
94.96
|
| Proceeds From Stock Option Exercised |
|
4.92
-78.89%
|
23.32
-55.96%
|
52.95
+2303.72%
|
2.20
|
| Changes In Cash |
|
28.66
+139.48%
|
-72.59
-181.53%
|
89.04
+480.27%
|
-23.41
|
| Beginning Cash Position |
|
85.18
-46.01%
|
157.78
+129.53%
|
68.74
-25.41%
|
92.15
|
| End Cash Position |
|
113.84
+33.64%
|
85.18
-46.01%
|
157.78
+129.53%
|
68.74
|
| Free Cash Flow |
|
-73.47
+70.78%
|
-251.44
-113.82%
|
-117.59
-29.77%
|
-90.62
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
0.03
-63.77%
|
0.07
+15.00%
|
0.06
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
0.00
|
0.00
|
| Amortization Of Securities |
|
-9.98
+57.06%
|
-23.23
-101.10%
|
-11.55
-1562.30%
|
-0.69
|
| Common Stock Issuance |
|
24.86
-96.20%
|
654.23
+111.20%
|
309.76
+226.20%
|
94.96
|
| Issuance Of Capital Stock |
|
24.86
-96.20%
|
654.23
+111.20%
|
309.76
+226.20%
|
94.96
|
| Net Preferred Stock Issuance |
|
—
|
9.40
-77.72%
|
42.18
|
0.00
|
| Preferred Stock Issuance |
|
—
|
9.40
-77.72%
|
42.18
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-13 View
- 8-K2026-04-09 View
- 42026-03-02 View
- 10-K2026-02-17 View
- 8-K2026-02-17 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 8-K2026-01-12 View
- 8-K2026-01-12 View
- 8-K2025-12-12 View
- 8-K2025-12-05 View
- 10-Q2025-11-04 View
- 8-K2025-11-04 View
- 8-K2025-10-20 View
- 8-K2025-09-08 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|